Zobrazeno 1 - 5
of 5
pro vyhledávání: '"S. P. Lukashyk"'
Autor:
S. P. Lukashyk, O. V. Aleinikova, V. M. Tsyrkunov, I. A. Karpov, Y. I. Isaykina, O. V. Krasko
Publikováno v:
Архивъ внутренней медицины, Vol 11, Iss 2, Pp 132-145 (2021)
Introduction. Liver cirrhosis (LC) is the final stage in the progression of chronic diffuse diseases. As common, late stages of LC do not respond to conservative treatment methods, so liver transplantation is the most effective method at this stage.
Externí odkaz:
https://doaj.org/article/8b7ce5cfc2e04fd6bc507895287572b2
Publikováno v:
Архивъ внутренней медицины, Vol 8, Iss 2, Pp 150-160 (2018)
Introduction. The importance of the HCV-infection is determined by the wide spread, progressive course, the formation of liver cirrhosis (LC) and hepatocellular carcinoma. The mechanisms of the effect of the virus on hepatic cells, the processes of f
Externí odkaz:
https://doaj.org/article/52a8e6fc75fa4b7cb16660866f9be3b0
Autor:
S. P. Lukashyk, I. A. Karpov
Publikováno v:
Архивъ внутренней медицины, Vol 7, Iss 3, Pp 171-180 (2017)
Information on etiology, epidemiology and clinical manifestations of acute liver failure is systemized. The review provides statistics on the frequency of its occurrence in different nosological manifestations, describes the most frequent developed c
Externí odkaz:
https://doaj.org/article/585114e9afe0478e865bcc1cf7770c39
Autor:
M. G. Siniauskaya, L.A. Anisko, O. G. Davydenko, S. P. Lukashyk, O.V. Krasko, I. A. Karpov, N. G. Danilenko
Publikováno v:
Клиническая микробиология и антимикробная химиотерапия, Vol 22, Iss 1, Pp 71-80 (2020)
Objective. To determine the efficacy and safety of direct-acting antiviral agents (DAA) in patients with chronic HCV infection and UGT1A1*28 polymorphism. Materials and Methods. An open-label, non-randomized, observational study to assess efficacy an
Publikováno v:
Cytology and Genetics. 53:407-417
The review is focused on the development of chronic viral hepatitis C in patients with a genetic defect in the hereditary hemochromatosis (HFE) gene that controls iron metabolism. The effect of HFE gene mutations on the patient’s susceptibility to